<DOC>
	<DOCNO>NCT03042741</DOCNO>
	<brief_summary>Atherosclerosis vaccine , V6 , two small-scale Phase II open label clinical trial . It show significant improvement lipid profile patient overweight obesity</brief_summary>
	<brief_title>Vaccine Against Atherosclerosis Patients With Overweight Problems Obesity</brief_title>
	<detailed_description>The propose study evaluate daily dose one V6 pill administer one month placebo-controlled , randomize , double-blind phase 3 trial men woman baseline waist diameter 90 80 cm respectively . The effect V6 assess change lipid profile , i.e. , LDL , HDL , TG TC ; anthropomorphic index , i.e. , circumference waist , mid-arm , hip ; arterial blood pressure fast glucose level baseline versus post-treatment timepoint .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Baseline waist diameter 90 80 cm men woman , respectively Pregnant lactate woman Individuals clinical symptom diseases opinion study investigator eligible participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>